Barrett’s Esophagus Test Identifies High-Risk Patients Missed by Standard Pathology
A study of 85 patients shows the TissueCypher test detected 15% with elevated cancer progression risk despite a non-dysplastic diagnosis.
Category: Uncategorized
Uncategorized
Latest
Uncategorized
Latest
Color Health Partners with CDC to Increase Access to COVID Testing
Color Health is providing free COVID testing through the CDC's Increasing Community Access to Testing program.
Uncategorized
Latest
Ortho Clinical Diagnostics, Thermo Fisher Scientific Partner on QC Solutions
Ortho Clinical Diagnostics has a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's Vitros QC Solutions to Vitros System customers worldwide.
Clinical Chemistry
Latest
Broader Screening Criteria Double Positive Results for Primary Aldosteronism, Study Finds
A study of 60,449 lab results found that using broader screening thresholds doubled detection rates of primary aldosteronism compared to Endocrine Society guidelines, according to research in Hypertension.
Flow Cytometry
Latest
Ultima Genomics Sequencing Platform Selected for 80,000-Sample UK Biobank Study
The project will analyze immune cells from blood samples to help researchers understand how differences in the immune system influence disease risk, progression, and treatment response.
Mass Spectrometry
Latest
University Spin-Out Launches to Commercialize Adrenal Cancer and Hormone Disorder Tests
IMS Solutions, a University of Birmingham and Imperial College London spin-out, has raised £1.1 million to commercialize mass spectrometry-based steroid biomarker tests for adrenal cancer and PMOS, with clinical validation underway.
Immunoassay
Latest
China Clears Quanterix and Innovita SIMOA Instruments and Blood-Based Neurology Tests
China’s NMPA has approved Quanterix and Innovita’s HD-X and SR-X immunoassay platforms and four blood-based neurology biomarker tests, expanding access to Alzheimer’s diagnostics in the Chinese clinical lab market.
Molecular Diagnostics
Latest
Medicare Begins Reimbursing Lucid Diagnostics’ EsoGuard Test
Medicare has begun reimbursing Lucid Diagnostics $1,938 per test for its EsoGuard Esophageal DNA Test under the Clinical Laboratory Fee Schedule. The company also closed a $15 million private placement to support commercialization.
Point-of-Care
Latest
Blood Test May Detect Brain Injuries Missed by CT Scans
Researchers identified blood levels of a brain injury biomarker that could help clinicians determine which patients need additional evaluation within 24 hours of trauma.